PCSK9 inhibition in statin-intolerant HeFH patients: What's new?

QR Code

PCSK9 inhibition in statin-intolerant HeFH patients: What's new?

Bibliographic Details
Main Authors:	Casula, M., Pirillo, A., Norata, Giuseppe, Catapano, A.
Format:	Journal Article
Published:	Sage Publications 2017
Online Access:	http://hdl.handle.net/20.500.11937/58841

Similar Items

PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
by: Norata, Giuseppe, et al.
Published: (2014)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives
by: Catapano, A., et al.
Published: (2017)

Targeting PCSK9 for hypercholesterolemia
by: Norata, Giuseppe, et al.
Published: (2014)

Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
by: Tibolla, G., et al.
Published: (2011)

PCSK9 inhibitors and dyslipidemia: The clinical evidence
by: Norata, Giuseppe
Published: (2014)

Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
by: Baragetti, A., et al.
Published: (2018)

Therapy and clinical trials: Aggressive statin therapy versus combined and emerging approaches
by: Catapano, A., et al.
Published: (2011)

Statins and periodontal inflammation: A pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?
by: Norata, Giuseppe, et al.
Published: (2014)

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
by: Baragetti, A., et al.
Published: (2017)

Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases
by: Pirillo, A., et al.
Published: (2016)

High-density lipoprotein subfractions - What the clinicians need to know
by: Pirillo, A., et al.
Published: (2013)

Statins and skeletal muscles toxicity: From clinical trials to everyday practice
by: Norata, Giuseppe, et al.
Published: (2014)

Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering
by: Norata, Giuseppe, et al.
Published: (2016)

Postprandial lipemia as a cardiometabolic risk factor
by: Pirillo, A., et al.
Published: (2014)

Vascular inflammation and low-density lipoproteins: Is cholesterol the link? A lesson from the clinical trials
by: Catapano, A., et al.
Published: (2017)

LOX-1, OxLDL, and atherosclerosis
by: Pirillo, A., et al.
Published: (2013)

HDLs, immunity, and atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2011)

Treating high density lipoprotein cholesterol (HDL-C): Quantity versus quality
by: Pirillo, A., et al.
Published: (2013)

HDL in infectious diseases and sepsis
by: Pirillo, A., et al.
Published: (2015)

Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?
by: Catapano, A., et al.
Published: (2017)

Strategies for the use of nonstatin therapies
by: Pirillo, A., et al.
Published: (2017)

Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’
by: Watts, G., et al.
Published: (2018)

Apolipoprotein C-III: From Pathophysiology to Pharmacology
by: Norata, Giuseppe, et al.
Published: (2015)

Intolerance of uncertainty in emotional disorders: What uncertainties remain?
by: Shihata, Sarah, et al.
Published: (2016)

The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis
by: Pirillo, A., et al.
Published: (2018)

Emerging role of high density lipoproteins as a player in the immune system
by: Norata, Giuseppe, et al.
Published: (2012)

HDL: To treat or not to treat?
by: Pirillo, A., et al.
Published: (2014)

HDL in innate and adaptive immunity
by: Catapano, A., et al.
Published: (2014)

Statins inhibit in vitro virulence phenotypes of Pseudomonas aeruginosa
by: Hennessey, E., et al.
Published: (2013)

No to religious intolerance
by: Abd Razak, Dzulkifli
Published: (2005)

In vivo and in vitro effects of phaleria macrocarpa (scheff.) boerl on low density lipoprotein and pcsk9 expression
by: Chong, Soo Ching
Published: (2011)

Performance evaluation of FH-OCDMA in the presence of GVD and SPM
by: Ng, Wai Ling, et al.
Published: (2005)

Phaleria macrocarpa (Scheff.) Boerl fruit aqueous extract enhances LDL receptor and PCSK9 expression in vivo and in vitro.
by: Chong, Soo Ching, et al.
Published: (2011)

Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia
by: Grigore, L., et al.
Published: (2013)

Leonurine: A new comer in the natural compounds affecting atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2012)

HDL and adaptive immunity: A tale of lipid rafts
by: Norata, Giuseppe, et al.
Published: (2012)

Association Of Single Nucleotide Polymorphisms (Snp) In Pcsk9 Gene With Lipid Analysis Among Iban And Bidayuh Ethnic Groups In Sarawak Population.
by: H. H., Hood, et al.
Published: (2015)

Milk intolerance, beta-casein and lactose
by: Pal, Sebely, et al.
Published: (2015)

The CD1d-natural killer T cell axis in atherosclerosis
by: Bondarenko, S., et al.
Published: (2014)

Studies in carpal tunnel syndrome and cold intolerance
by: Salem-Saqer, Khaled
Published: (2008)